This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Cheetham, C. Articles by Green, D. Search for Related Content PubMed PubMed Citation Articles by Cheetham, C. Articles by Green, D.

Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes

Craig Cheetham, BSc^a, Julie Collis, BSc^a, Gerard O’Driscoll, MB, BCh, BAO, FRACP^b, Kim Stanton, MB, BS, FRACP^||, Roger Taylor, MB, BS, FRACP^b,e and Daniel Green, PhD^a,b

^a Department of Human Movement and Exercise Science,The University of Western Australia, Perth, Australia
^e Department of Medicine, The University of Western Australia, Perth, Australia
^b Department of Cardiology, Royal Perth Hospital and West Australian Heart Research Institute, Perth, Australia; Department of Cardiology
Cardiac Transplant Unit, Royal Perth Hospital and West Australian Heart Research Institute, Perth, Australia
^|| Endocrinology and Diabetic Unit, Royal Perth Hospital and West Australian Heart Research Institute, Perth, Australia

View larger version (13K): [in a new window]   Figure 1 Forearm blood flow (FBF) response to three doses of acetylcholine (ACh) following placebo or losartan administration for four weeks. Forearm blood flow is expressed as the percentage change in the ratio of infusion arm to noninfusion arm flows relative to the baseline period preceding the administration of ACh. Values are means ± SE. ACh response significantly increased following losartan administration (p < 0.01, ANOVA; p < 0.02 at 10 µg/min, p < 0.02 at 20 µg/min, p < 0.05 at 40 µg/min, t tests).

View larger version (14K): [in a new window]   Figure 2 Forearm blood flow (FBF) response to three doses of sodium nitroprusside (SNP) following placebo or losartan administration for four weeks. Forearm blood flow is expressed as the percentage change in the ratio of infusion arm to noninfusion arm flows relative to the baseline period preceding the administration of SNP. Values are means ± SE. No change in SNP response was evident following losartan administration (p = 0.6, ANOVA; at each infusion rate p > 0.4, t tests).

View larger version (13K): [in a new window]   Figure 3 Forearm blood flow (FBF) response to three doses of NG monomethyl-L-arginine (LNMMA) following placebo or losartan administration for four weeks. Forearm blood flow is expressed as the percentage change in the ratio of infusion arm to noninfusion arm flows relative to the baseline period preceding the administration of LNMMA. Values are means ± SE. No change in LNMMA response was evident following losartan administration (p = 0.5, ANOVA; at each infusion rate p > 0.2, t tests).